PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Key Points

• PolyPid reported quarterly EPS of $(0.35), beating analyst expectations of $(0.38) by $0.03.
• The FDA accepted D-PLEX100’s NDA for priority review, with a PDUFA decision target of November 28, 2026. PolyPid also signed a U.S. and Canadian commercialization agreement with Azurity worth $30 million in upfront and near-term milestone payments, plus potential additional milestones exceeding $290 million.
• Azurity is preparing for an early 2027 commercial launch, while PolyPid expects its cash and partnership proceeds to fund operations into 2028 without an immediate financing need.

PolyPid (NASDAQ:PYPD - Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.03, FiscalAI reports.

Here are the key takeaways from PolyPid's conference call:

• FDA accepted D-PLEX100’s NDA for filing with priority review and no filing-review issues identified; the PDUFA goal date is November 28, 2026.
• PolyPid signed an exclusive U.S. and Canadian commercialization agreement with Azurity, securing $30 million in upfront and near-term milestones, eligibility for more than $290 million in additional milestones, tiered royalties, and a transfer price on manufactured units.
• Azurity has begun launch preparations, including sales-force expansion, hospital contracting, medical affairs, and reimbursement efforts, with a commercial launch still expected in early 2027. The partnership will also fund label-expansion development in additional surgical indications.
• Management expects its cash resources, partnership proceeds, and potential future payments to fund operations into 2028, and said it has no immediate financing needs.
• PolyPid plans to submit D-PLEX100’s marketing authorization application to the European Medicines Agency in the third quarter of 2026 and is preparing for the FDA pre-approval manufacturing inspection; management reported productive regulatory discussions but approval remains subject to review.

PolyPid Stock Down 2.1%

Shares of PYPD stock traded down $0.10 during mid-day trading on Wednesday, reaching $4.63. The company's stock had a trading volume of 171,936 shares, compared to its average volume of 127,516. The firm has a market capitalization of $88.35 million, a PE ratio of -2.42 and a beta of 1.41. The company's 50 day simple moving average is $4.73 and its 200-day simple moving average is $4.57. PolyPid has a 12-month low of $3.06 and a 12-month high of $5.73.

Institutional Trading of PolyPid

Several large investors have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets lifted its stake in shares of PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company's stock worth $32,000 after purchasing an additional 3,500 shares in the last quarter. HighTower Advisors LLC acquired a new stake in shares of PolyPid in the fourth quarter valued at about $44,000. Jane Street Group LLC purchased a new stake in shares of PolyPid during the 4th quarter valued at about $66,000. XTX Topco Ltd raised its holdings in shares of PolyPid by 50.0% during the 4th quarter. XTX Topco Ltd now owns 32,661 shares of the company's stock valued at $142,000 after buying an additional 10,888 shares during the period. Finally, ADAR1 Capital Management LLC acquired a new position in PolyPid during the 4th quarter worth approximately $451,000. 26.47% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the company. HC Wainwright reaffirmed a "buy" rating and issued a $13.00 target price on shares of PolyPid in a research report on Tuesday, July 21st. Craig Hallum set a $12.00 price target on PolyPid in a research report on Wednesday, July 22nd. Finally, Weiss Ratings upgraded PolyPid from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, June 23rd. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $11.33.

PolyPid Company Profile

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source